The presently disclosed subject matter provides antibodies that bind to GPRC5D and methods of using the same.

The present invention is directed to modified CFTR proteins or fragments thereof that contain single or multiple amino acid mutations to improve the structural stability of such CFTR proteins and/or fragments. Specifically, the modified CFTR proteins or fragment thereof differ from the wild-type human CFTR protein or fragment thereof by the presence of four or more mutations selected from V150D, M470V, S492P, F494N, S495P, A534P, I539T, G550E, G551D, R553Q, R555K, Q637R, S1255L, K1334G, S1359A, E1371Q, H1402S, Q1411D, and any combination thereof, such that the stability of the polypeptide is increased relative to that of the wild-type human CFTR polypeptide or fragment thereof.

Methods and reagents for diagnosing, prognosing, and treating systemic lupus erythematosus (SLE) are disclosed, involving calculating an SLE risk score for a subject based on a level of each of an erythrocyte C4d (EC4d) marker, a B-cell C4d (BC4d) marker, anti-nuclear antibodies (ANA), and optional rule-out markers.

Provided is a device or method for detection of leukocytes in a disease state or leukocytes in an abnormal state, or diagnosing a leukocyte-related disease, according to the device or method according to an aspect, it is possible to detect leukocytes in a disease state or leukocytes in an abnormal state at an early stage using a small amount of sample isolated from a subject, and thus, there is an effect that allows diagnosis of a leukocyte-related disease, for example, inflammation, an infectious disease, an immune disease, a metabolic disease, or cancer, etc.

The present disclosure relates generally to methods and systems for detecting, characterizing biomarker expression and morphological analysis in cell samples. The methods allow for the use of automated platforms to stain cells for molecular biomarkers and Romanowsky-type staining for cell morphology analysis. Cells that are prepared according to the disclosed methods can also be used in the diagnosis of certain conditions.

Methods for detecting cancer cells, or aggressive cancers, by measuring levels of cardiolipin molecules are provided. Methods of treating identified cancers are likewise provided.

Disclosed herein are methods of detecting the presence or absence of exosomes, the method comprising detecting an exosomal biomarker in a sample obtained from a subject. Also disclosed herein is a system and a biosensor, each for detecting an exosomal biomarker as disclosed herein.

The invention generally relates to antibodies that bind to human folate receptor 1 and diagnostic assays for folate receptor 1-based therapies. Methods of using the antibodies to monitor therapy are further provided.

Compositions including an antibody single-chain variable fragment (scFv) conjugate that specifically binds to ROR1 tumor-associated antigen are provided. The anti-ROR1 scFv antibody and conjugates may include a biologically-active molecule. Such conjugates may comprise a chimeric receptor to direct T cells to respond to ROR1 cancer cells, Methods to use the scFV conjugates to target cells expressing ROR1 for therapeutic and diagnostic purposes are also provided.

There is provided a method of identifying a neutrophil progenitor, the method comprising: determining an expression of at least one biomarker selected from the group consisting of: CD71, LOX-1, CD164, CD112, CD181, TACSTD2, CD11b and CD49d in a cell. In various embodiments, the cell is identified as a neutrophil progenitor when it is determined to have at least one of the following expression profiles: CD71.sup.hi/+, LOX-1.sup.int/lo/−, CD164.sup.hi/+, CD112.sup.hi/+, CD181.sup.int/lo/−, TACSTD2.sup.hi/+, CD11b.sup.lo/− and/or CD49d.sup.int/hi/+. Also disclosed are a method of sorting and/or separating neutrophil progenitors from a cell population, a composition that is enriched in neutrophil progenitors and related uses and methods.